Verrica Pharmaceuticals Inc (VRCA) FinancialsVRCAVerrica Pharmaceuticals Inc

Evaluating the bottom line, Verrica Pharmaceuticals Inc maintains a gross margin of 85.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -194.46%, while the net margin is -224.38%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively VRCA converts its operational activities into shareholder value.

In the context of the broader market, VRCA competes directly with industry leaders such as RNTX and CLNN. With a market capitalization of $55.15M, it holds a significant position in the sector. When comparing efficiency, VRCA's gross margin of 85.02% stands against RNTX's N/A and CLNN's 71.43%. Such benchmarking helps identify whether Verrica Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Verrica's total revenue for Q2 2026 was $5.9 million, down from $12.7 million year-over-year, but it reported a gross profit margin of 85.02%, indicating strong product demand despite overall revenue decline.